MŁMałgorzata Łodyga

Małgorzata Łodyga

*This is an algorithmically generated author record based on publicly available information.

Małgorzata Łodyga has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    May Patients with Recurrent Venous Disease Benefit from Sequential Treatment More than Those without Previous Intervention? A Single-Center Retrospective Study on the Safety and Efficacy of Abdominal and Pelvic Veins Embolization in Sequential Approach

    by Cezary Szary, Justyna Wilczko-Kucharska, Krzysztof Celejewski, Małgorzata Łodyga, Marcin Napierala, Dominika Plucinska, Siavash Swieczkowski-Feiz, Jerzy Leszczynski, Michal Zawadzki, Tomasz Grzela

    Background/Objective: The endovenous embolization of insufficient abdominal/pelvic veins is the preferred method of treatment. Also, it seems to be crucial in the treatment of lower limb vein insufficiency, particularly in recurrent disease. This study aimed to evaluate of pelvic vein embolization safety and its impact on the short-term outcome in the sequential treatment of venous disease. Methods: A retrospective analysis involved data from 506 female patients with venous disease involving abdominal and pelvic veins. All records were extracted from the medical database and included patient history, imaging reports as well as pre- and post-operative surveys. Results: Among the patients analyzed, 37.2% underwent some venous intervention in the past, with significant differences in symptom severity between groups. The embolization procedure revealed a high safety profile, with no serious complications. Pain during and after the procedure was generally low, with significantly lower pain scores in patients with recurrence. In patients who required left renal vein venoplasty a 1.7-fold increased risk of lumbar pain after embolization and venoplasty procedure was observed. Overall, 66.6% of patients reported improvement in pelvic symptoms and 72.1% experienced improvement in leg symptoms. The full sequential treatment protocol (abdominal, pelvic, and leg compartment) demonstrated superior outcomes in leg symptom improvement compared to embolization alone. Conclusions: Pelvic vein embolization is a safe and effective method of treatment, significantly improving both pelvic and leg symptoms, particularly in patients with a history of previous interventions in lower limb veins. Further studies are warranted to validate our findings and further refine treatment protocols.


  • Open Access

    Safety of a simplified electrophysiological method of transseptal puncture. A single center’s experience

    by Małgorzata Łodyga, Piotr Urbanek, Michał Orczykowski, Damian Łasocha, Maria Bilińska, Łukasz J. Szumowski

  • Open Access

    Risk factors of atrial fibrillation recurrence despite successful radiofrequency ablation of accessory pathway: At 11 years of follow-up

    by Michał Orczykowski, Piotr Urbanek, Robert Bodalski, Paweł Derejko, Grzegorz Warmiński, Małgorzata Łodyga, Damian Łasocha, Łukasz Mazurkiewicz, Maciej Dąbrowski, Paweł Tyczyński, et al.

    Background: Previous reports on patients with radiofrequency catheter ablation (RFCA) of accessory pathway (AP) and atrial fibrillation (AF) include only short follow-up periods. The aim of this study was to analyse predictors of recurrence of AF in patients after successful RFCA of APs over long term follow-up periods. Methods: Of the 1,007 patients who underwent non-pharmacological treatment of Aps ( between the years 1993–2008), data of 100 consecutive patients were retrospectively analyzed (75 men, mean age 43.6 ± 14.7), with the longest period of follow-up (mean 11.3 ± 3.5 years) after successful RFCA of AP. In Group 1, there were 72 patients (54 M, mean age 40.66 ± 13.85 years) without documented episodes of AF after RFCA of AP. Group 2 consisted of 28 patients (21 men, mean age 50.79 ± 14.49 years) with AF episodes despite successful elimination of AP. Results: In univariate analysis, patients from Group 1 were significantly younger at the time of ablation than patients from Group 2 (40.66 ± 13.85 vs. 50.79 ± 14.49 years; p = 0.002), had shorter history of AF episodes (4.11 ± 4.07 vs. 8.25 ± 7.50 years; p = 0.024) and had more frequently documented atrial tachycardia (AT) prior to ablation (3.39 vs. 20.00 years; p = 0.022). In multivariate analysis, the history of AF in years (p = 0.043), was an independent risk factor for AF recurrences. Conclusions: Older patient age, longer history of AF and AT prior to RFCA of APs identified a subgroup of patients who required additional treatment. In the multivariate analysis, the history of AF in years (p = 0.043) was a risk factor for AF recurrence. Background: Previous reports on patients with radiofrequency catheter ablation (RFCA) of accessory pathway (AP) and atrial fibrillation (AF) include only short follow-up periods. The aim of this study was to analyse predictors of recurrence of AF in patients after successful RFCA of APs over long term follow-up periods. Methods: Of the 1,007 patients who underwent non-pharmacological treatment of Aps ( between the years 1993–2008), data of 100 consecutive patients were retrospectively analyzed (75 men, mean age 43.6 ± 14.7), with the longest period of follow-up (mean 11.3 ± 3.5 years) after successful RFCA of AP. In Group 1, there were 72 patients (54 M, mean age 40.66 ± 13.85 years) without documented episodes of AF after RFCA of AP. Group 2 consisted of 28 patients (21 men, mean age 50.79 ± 14.49 years) with AF episodes despite successful elimination of AP. Results: In univariate analysis, patients from Group 1 were significantly younger at the time of ablation than patients from Group 2 (40.66 ± 13.85 vs. 50.79 ± 14.49 years; p = 0.002), had shorter history of AF episodes (4.11 ± 4.07 vs. 8.25 ± 7.50 years; p = 0.024) and had more frequently documented atrial tachycardia (AT) prior to ablation (3.39 vs. 20.00 years; p = 0.022). In multivariate analysis, the history of AF in years (p = 0.043), was an independent risk factor for AF recurrences. Conclusions: Older patient age, longer history of AF and AT prior to RFCA of APs identified a subgroup of patients who required additional treatment. In the multivariate analysis, the history of AF in years (p = 0.043) was a risk factor for AF recurrence.